Journal article · 2015 · Open access
Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens
BMC Infectious Diseases, 15(1), 558 · Published 1 December 2015 · DOI 10.1186/s12879-015-1276-2
In brief
“Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens” is a 2015 journal article by The IMPROV Study Group, published in BMC Infectious Diseases. OpenAlex counts 279 citations as of 20 November 2026. It is open access under a CC BY licence: the full text is free to read at BMC Infectious Diseases.
- Citations
- 279
- Most cited in
- 2021 (86)
- Field-weighted impact
- 31.03
- References
- 10
- Authors
- 1
Abstract
BACKGROUND: Plasmodium vivax malaria is a major cause of morbidity and recognised as an important contributor to mortality in some endemic areas. The current recommended treatment regimen for the radical cure of P. vivax includes a schizontocidal antimalarial, usually chloroquine, combined with a 14 day regimen of primaquine. The long treatment course frequently results in poor adherence and effectiveness. Shorter courses of higher daily doses of primaquine have the potential to improve adherence and thus effectiveness without compromising safety. The proposed multicentre randomised clinical trial aims to provide evidence across a variety of endemic settings on the safety and efficacy of high dose short course primaquine in glucose-6-phosphate-dehydrogenase (G6PD) normal patients. DESIGN: This study is designed as a placebo controlled, double blinded, randomized trial in four countries: Indonesia, Vietnam, Afghanistan and Ethiopia. G6PD normal patients diagnosed with vivax malaria are randomized to receive either 7 or 14 days high dose primaquine or placebo. G6PD deficient (G6PDd) patients are allocated to weekly primaquine doses for 8weeks. All treatment is directly observed and recurrent episodes are treated with the same treatment than allocated at the enrolment episode. Patients are followed daily until completion of treatment, weekly until 8 weeks and then monthly until 1 year after initiation of the treatment. The primary endpoint is the incidence rate (per person year) of symptomatic recurrent P. vivax parasitaemia over 12 months of follow-up, for all individuals, controlling for site, comparing the 7 versus 14-day primaquine treatment arms. Secondary endpoints are other efficacy measures such as incidence risk at different time points. Further endpoints are risks of haemolysis and severe adverse events. DISCUSSION: This study has been approved by relevant institutional ethics committees in the UK and Australia, and all participating countries. Results will be disseminated to inform P. vivax malaria treatment policy through peer-reviewed publications and academic presentations. Findings will contribute to a better understanding of the risks and benefits of primaquine which is crucial in persuading policy makers as well as clinicians of the importance of radical cure of vivax malaria, contributing to decreased transmission and a reduce parasite reservoir. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01814683 . Registered March 18, 2013.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
The IMPROV Study Group. (2015). Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens. BMC Infectious Diseases, 15(1), 558. https://doi.org/10.1186/s12879-015-1276-2
MLA 9
The IMPROV Study Group. “Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens.” BMC Infectious Diseases, vol. 15, no. 1, 2015, p. 558. https://doi.org/10.1186/s12879-015-1276-2.
Chicago
The IMPROV Study Group. 2015. “Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens.” BMC Infectious Diseases 15 (1): 558. https://doi.org/10.1186/s12879-015-1276-2.
Harvard
The IMPROV Study Group (2015) ‘Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens’, BMC Infectious Diseases, 15(1), p. 558. doi:10.1186/s12879-015-1276-2.
IEEE
The IMPROV Study Group, “Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens,” BMC Infectious Diseases, vol. 15, no. 1, p. 558, 2015, doi: 10.1186/s12879-015-1276-2.
BibTeX
@article{theimprovstudygroup2015improving,
title = {{Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens}},
author = {The IMPROV Study Group},
journal = {BMC Infectious Diseases},
year = {2015},
volume = {15},
number = {1},
pages = {558},
doi = {10.1186/s12879-015-1276-2},
url = {https://doi.org/10.1186/s12879-015-1276-2}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2015 | 6 | |
| 2016 | 21 | |
| 2017 | 52 | |
| 2018 | 37 | |
| 2019 | 32 | |
| 2020 | 40 | |
| 2021 | 86 | |
| 2023 | 4 | |
| 2026 | 1 |
Its field-weighted citation impact is 31.03: it has been cited 31.03 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- vivax malaria
- radical cure
- primaquine
- glucose-6-phosphate dehydrogenase deficiency
- medication adherence
- hemolysis
- antimalarial treatment efficacy
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
The IMPROV Study Group. (2015). Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens. BMC Infectious Diseases, 15(1), 558. https://doi.org/10.1186/s12879-015-1276-2
How many times has this paper been cited?
279 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at BMC Infectious Diseases: sign in and open the PDF from this page.
Who wrote this paper?
The IMPROV Study Group.
What is the DOI of this paper?
10.1186/s12879-015-1276-2, permanently at https://doi.org/10.1186/s12879-015-1276-2. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.